Scisparc Ltd (SPRC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.49 (+0.90%), Market cap $0.00B, P/E ratio 0.04, 52-week low–high $0.30 ~ $9.03.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical tri
Financial statements, price targets, institutional (13F) holdings and related news for Scisparc Ltd are updated in real time on BlackAll Trade.
Scisparc Ltd trades at $4.49 (+0.90%). Real-time quotes and charts are available on BlackAll Trade.
Scisparc Ltd has a market cap of about $0.00B. Its P/E ratio is 0.04.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheime